|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 215.58 USD | +4.74% |
|
+0.25% | +1.10% |
| Capitalization | 11.28B 13.23B 10.45B 9.83B 18.29B 1,204B 19.62B 121B 47.65B 573B 49.62B 48.6B 2,090B | P/E ratio 2025 * |
-52.9x | P/E ratio 2026 * | 44.6x |
|---|---|---|---|---|---|
| Enterprise value | 11.09B 13.01B 10.28B 9.67B 17.99B 1,184B 19.3B 119B 46.86B 563B 48.8B 47.8B 2,055B | EV / Sales 2025 * |
15.4x | EV / Sales 2026 * | 8.05x |
| Free-Float |
97.58% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Ascendis Pharma A/S
More recommendations
More press releases
More news
| 1 day | +4.74% | ||
| 1 week | +0.25% | ||
| Current month | +1.10% | ||
| 1 month | +7.80% | ||
| 3 months | +5.05% | ||
| 6 months | +26.89% | ||
| Current year | +1.10% |
| 1 week | 200.68 |  | 219 |
| 1 month | 188.08 | | 221.75 |
| Current year | 188.08 | | 221.75 |
| 1 year | 118.03 | | 229.94 |
| 3 years | 64.33 | | 229.94 |
| 5 years | 61.58 | | 229.94 |
| 10 years | 11.92 | | 229.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
CEO | Chief Executive Officer | 67 | 2007-11-30 |
Scott Smith
DFI | Director of Finance/CFO | 53 | 2016-08-07 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 53 | 2020-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
BRD | Director/Board Member | 67 | 2007-11-30 |
Albert Cha
CHM | Chairman | 54 | 2021-05-27 |
Lisa Bright
BRD | Director/Board Member | 59 | 2017-03-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.74% | +0.25% | +68.25% | +75.24% | 13.23B | |
| +0.52% | -1.90% | -4.00% | +10.59% | 48.34B | |
| -1.68% | -3.26% | +18.41% | +4.51% | 39.8B | |
| -1.16% | -4.78% | +59.12% | +25.47% | 36.99B | |
| +0.24% | -6.33% | +19.14% | +39.10% | 30.67B | |
| -3.38% | -3.11% | +188.46% | +322.31% | 22.47B | |
| -1.39% | -0.99% | +78.57% | +162.90% | 16.97B | |
| Average | +0.57% | -2.44% | +61.13% | +91.45% | 29.78B | |
| Weighted average by Cap. | +0.17% | -2.89% | +46.93% | +66.36% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 720M 845M 667M 627M 1.17B 76.87B 1.25B 7.7B 3.04B 36.55B 3.17B 3.1B 133B | 1.32B 1.55B 1.22B 1.15B 2.14B 141B 2.3B 14.13B 5.58B 67.08B 5.81B 5.69B 245B |
| Net income | -196M -230M -181M -171M -318M -20.91B -341M -2.09B -827M -9.94B -862M -844M -36.28B | 253M 297M 234M 220M 410M 27B 440M 2.7B 1.07B 12.84B 1.11B 1.09B 46.84B |
| Net Debt | -187M -219M -173M -163M -303M -19.93B -325M -2B -788M -9.47B -821M -804M -34.58B | -640M -750M -593M -557M -1.04B -68.3B -1.11B -6.84B -2.7B -32.48B -2.81B -2.76B -119B |
More financial data
* Estimated data
Employees
1,017
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-20 | 215.58 $ | +4.74% | 677,863 |
| 26-01-16 | 205.83 $ | -4.28% | 693,068 |
| 26-01-15 | 215.04 $ | -1.05% | 303,280 |
| 26-01-14 | 217.32 $ | +1.06% | 482,829 |
| 26-01-13 | 215.05 $ | +3.01% | 1,364,742 |
Delayed Quote Nasdaq, January 20, 2026 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
183.74EUR
Average target price
230.53EUR
Spread / Average Target
+25.47%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ASND Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition